Don’t invest unless you’re prepared to lose all the money you invest. This is a high‑risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more.


Verinnogen named one of Cofinitive 21 to Watch

Congratulations to portfolio company Verinnogen for making the Cofinitive #21toWatch, Top 21 for 2024!

This is great recognition of the Verinnogen team's work to help transform pre-clinical oncology research with their innovative device for measuring physical properties of 3D surfaces.

Isaac Johnson, CEO and Co-Founder said: “Verinnogen exists to bring new enabling technologies to under-served scientific sectors, starting with this conceptually simple but brilliantly innovative tool to improve the way new cancer therapies are assessed in vivo, getting early-stage, transformative treatments through to clinical trials, and patients, faster.

“We’re grateful for this recognition, and to all our partners, for helping us highlight that better tools means better science.”